P772: LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PNH PROVIDES DURABLE CONTROL OF INTRAVASCULAR HEMOLYSIS WITH LOW INCIDENCE OF MAJOR ADVERSE VASCULAR EVENTS AND DEATH.

• Austin Kulasekararaj,
• Robert Brodsky,
• Morag Griffin,
• Alexander Röth,
• Caroline Piatek,
• Masayo Ogawa,
• Ji Yu,
• Yogesh Patel,
• Fernando Ataulfo Gonzalez Fernandez,
• Jun-Ichi Nishimura,
• Régis Peffault de Latour,
• Jeff Szer,
• Jong Wook Lee

Affiliations

Austin Kulasekararaj

1 Kings College Hospital, National Institute of Health Research/Wellcome King’s College London, United Kingdom

Robert Brodsky

2 John Hopkins Medicine, Division of Hematology, United States

Morag Griffin

3 St James’ Hospital, NHS Teaching Hospitals, United Kingdom

Alexander Röth

4 West German Cancer Center, University Hospital Essen, Germany

Caroline Piatek

5 Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, USC Norris Comprehensive Cancer Center

Masayo Ogawa

6 Alexion, AstraZeneca Rare Disease

Ji Yu

6 Alexion, AstraZeneca Rare Disease

Yogesh Patel

6 Alexion, AstraZeneca Rare Disease

Fernando Ataulfo Gonzalez Fernandez

7 Service of Hematology, Hospital Clínico San Carlos, Universidad Complutense

Jun-Ichi Nishimura

8 Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan

Régis Peffault de Latour

9 Hôpital Saint-Louis AP-HP, France

Jeff Szer

10 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital

Jong Wook Lee

11 Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Department of Hematology